Production (Stage)
Revelation Biosciences, Inc.
REVB
$2.97
$0.103.48%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -2.67% | -1.88% | 10.20% | 23.33% | 25.17% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -8.62% | -7.87% | 13.22% | 59.59% | 51.56% |
| Operating Income | 8.62% | 7.87% | -13.22% | -59.59% | -51.56% |
| Income Before Tax | -60.79% | -12,400.83% | -1,873.22% | -781.72% | -560.43% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -60.79% | -12,400.83% | -1,873.22% | -781.72% | -560.43% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -60.79% | -12,400.83% | -1,873.22% | -781.72% | -560.43% |
| EBIT | 8.62% | 7.87% | -13.22% | -59.59% | -51.56% |
| EBITDA | 8.69% | 7.93% | -13.24% | -59.82% | -51.78% |
| EPS Basic | -160.54% | -- | -- | -- | -- |
| Normalized Basic EPS | -160.54% | -- | -- | -- | -- |
| EPS Diluted | -160.69% | -- | -- | -- | -- |
| Normalized Diluted EPS | -160.54% | -- | -- | -- | -- |
| Average Basic Shares Outstanding | 2,231.28% | -- | -- | -- | -- |
| Average Diluted Shares Outstanding | 2,231.28% | -- | -- | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |